Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TUG1ASO
- Development stage
- Unknown
- Lead developer
- Nagoya University
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
TUG1ASO is a novel nucleic acid therapeutic consisting of an antisense oligonucleotide (ASO) targeting the long noncoding RNA (lncRNA) Taurine-upregulated gene 1 (TUG1). It is formulated with a Y-shaped block catiomer drug delivery system, creating a nanoparticle approximately 18 nm in size. TUG1 is highly expressed in glioblastoma and plays a critical role in resolving R-loop formation to maintain tumor cell proliferation. By targeting TUG1, the drug aims to disrupt these processes and inhibit tumor growth. It is currently being evaluated in investigator-initiated Phase I clinical trials for the treatment of recurrent glioblastoma.
- Other names
- TUG1-targeted antisense oligonucleotideTUG-1-targeted antisense oligonucleotideTUG 1-targeted antisense oligonucleotideTUG1-ASOTUG-1-ASOTUG 1-ASO
02
Targets
TUG1
Beyond the preview
Go deeper on TUG1ASO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TUG1ASO.